Biosysen
倍生生物科技（深圳）有限公司
A Shenzhen (Guangming Science City) 'software-defined' synthetic-biology house that designs and licenses engineered industrial microbial strains — it explicitly runs a strain library (ArchiCel®) and a strain-licensing business plus a daily-chemicals (日化) pipeline, so it maps directly onto Pure Advance's microbial-cell-factory + bio-derived-actives priority.
- Location
- Guangming District (Fenghuang Subdistrict) · Shenzhen
- Visit window
- From the Nanshan base · Jul 13–31
- Source status
- high confidencecandidate
Next action
Prepare the private outreach route and meeting ask; keep contact details out of the app.
Why now: Visit window · From the Nanshan base · Jul 13–31
What they do
A software-driven synthetic-biology company that treats industrial-microbe design as engineering, building modular genome 'code' libraries and a rapid-iteration platform around its Architected Cell (ArchiCel®) genomic-design unit. It runs four platforms (bioinformatics/genome design, genome manufacturing, quantitative-omics, pilot-scale production), cites ~2,000+ production and 40,000+ R&D/engineered strains, and monetises via platform-tech transfer, self-incubated pipelines and strain licensing; early pipelines are craft beer/fermented soda, IVD reagents and daily-chemical/personal-care actives.
Why it matters
Strong fit to the lead platform (microbial-resource discovery + engineered cell factories): a GBA company whose explicit products are an engineered-strain library (ArchiCel®) and strain licensing plus a software-defined AI genome-design platform — structurally open to handing over IP/strains rather than only selling finished goods. A stated 日化/personal-care pipeline is a natural on-ramp to a Coolvex-type topical active, and the founder's ex-BGI background lends scientific credibility.
Caveat: traction to date is in beverages, so the personal-care line may be roadmap rather than catalogue-ready.
Visit objective & route
Explore strain-access / license-in and co-development for the lead biocontrol/microbial-cell-factory platform (ArchiCel strain library + strain-licensing), and confirm whether an actual personal-care/日化 active exists as a Coolvex on-ramp vs a roadmap.
Approach route
Direct outreach via the company website with a 日化/strain-licensing focus so they bring the right person; pair with a Guangming synbio day (National Biomanufacturing Innovation Center + other Guangming synbio firms).
Talking points
- Whether strains/cell-factory chassis are licensable for an external partner's agri-biocontrol / biomanufacturing discovery programme.
- Whether a real personal-care / 日化 active or licensable skin-relevant strain exists today (Coolvex) vs a roadmap.
- What classes of organisms (yeast, bacteria, etc.) the strain library covers, and current strain counts.
- Export / overseas-licensing precedent and IP terms for strain licensing.
Open questions
- Whether strains/cell-factory chassis are licensable for an external partner's agri-biocontrol/biomanufacturing discovery programme (crux of the lead-platform fit).
- Whether a real personal-care/日化 active or licensable skin-relevant strain exists today vs a roadmap.
- Latest funding round/investors after 2022; current stage and runway.
- Exact current strain counts and what classes of organisms.
- Which Guangming site to actually visit (HQ office vs R&D centre vs pilot base).
- Whether there is a dedicated partnerships/BD lead to route to.
- Any export/overseas-licensing precedent and IP terms for strain licensing.
Risks & unknowns
- Commercial traction to date is in beverages; the personal-care/日化 line may be roadmap rather than catalogue-ready.
- Smaller and younger than larger peers — treat as a co-development/strain-access partner, not a turnkey supplier.
- Post-2022 funding/runway not verified.
- Strain counts are company-disclosed via secondary coverage.
Private-pack boundary